Search results
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World...
FOX 5 San Diego· 3 days agoDALLAS, May 7, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that ...
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating...
NBC 17 Raleigh· 3 days agoNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, announces new analyses from its Phase 2b PARADIGM clinical ...
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of...
The Mammoth Times· 6 days agoSentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoWebinar, moderated by Cantor Fitzgerald, will be held on Monday, May 13, 2024, at 2:00 p.m. ET Discussion will feature Dr. Michel Michaelides, leading expert in the field of inherited eye disease in adults and children SAN DIEGO, May 06
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With...
Digital Journal· 20 hours agoRegistrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated